ERBB2 and gastric cancer: In this study, by evaluating the longitudinal changes of ctDNA in plasma derived from advanced GC patients during HER2‐targeted therapy, we seek to identify the genetic information that directed responses and prognosis, and to explore additional therapeutic options for advanced GC.